Efficacy and Safety of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin Added to Ongoing Metformin Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Alone
The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
OBJECTIVE—The efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, added to ongoing metformin therapy, were assessed in patients with type 2 diabetes who had inadequate glycemic control (HbA1c [A1C] ≥7 and ≤10%) with metformin alone. RESEARCH DESIGN AND METHODS—After a screening diet/exercise run-in period, a metformin dose titration/stabilization period, and a 2-week, single-blind, placebo run-in period, 701 patients, aged 19–78 years, with mild to moderate hyperglycemia (mean A1C 8.0%) receiving ongoing metformin (≥1,500 mg/day) were randomly assigned to receive the addition of placebo or sitagliptin 100 mg once-daily in a 1:2 ratio for 24 weeks. Patients exceeding specific glycemic limits were provided rescue therapy (pioglitazone) until the end of the study. The efficacy analyses were based on an all-patients-treated population using an ANCOVA and excluded data obtained after glycemic rescue. RESULTS—At week 24, sitagliptin treatment led to significant reductions compared with placebo in A1C (−0.65%), fasting plasma glucose, and 2-h postmeal glucose. Fasting insulin, fasting C-peptide, fasting proinsulin-to-insulin ratio, postmeal insulin and C-peptide areas under the curve (AUCs), postmeal insulin AUC–to–glucose AUC ratio, homeostasis model assessment of β-cell function, and quantitative insulin sensitivity check index were significantly improved with sitagliptin relative to placebo. A significantly greater proportion of patients achieved an A1C <7% with sitagliptin (47.0%) than with placebo (18.3%). There was no increased risk of hypoglycemia or gastrointestinal adverse experiences with sitagliptin compared with placebo. Body weight decreased similarly with sitagliptin and placebo. CONCLUSIONS—Sitagliptin 100 mg once-daily added to ongoing metformin therapy was efficacious and well tolerated in patients with type 2 diabetes who had inadequate glycemic control with metformin alone.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, studies report an increased incidence of nasopharyngitis in subjects randomly assigned to DPPIV inhibitor 35,38,40 ; in 1 study, 1 of 175 sitagliptin-treated subjects was hospitalized for angioedema.41”
From Dipeptidyl Peptidase IV in Angiotensin-Converting Enzyme Inhibitor–Associated Angioedema (2008) · cites this paper as [40]
Citations
Cites
MENTLEIN, R., GALLWITZ, B., & SCHMIDT, W. E. (1993) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1993.tb17986.x · Cited by 1,161
Oral Antihyperglycemic Therapy for Type 2 Diabetes: Scientific Review
Inzucchi, S. E. (2002) · JAMA · doi:10.1001/jama.287.3.360 · Cited by 1,065
Kim, D., Wang, L., Beconi, M., Eiermann, G. J., Fisher, M. H., He, H., Hickey, G. J., Kowalchick, J. E., Leiting, B., Lyons, K., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm0493156 · Cited by 822
Deacon, C. F., Johnsen, A. H., & Holst, J. J. (1995) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.80.3.7883856 · Cited by 792
Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans
Holst, J. J., & Gromada, J. (2004) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00545.2003 · Cited by 611
Standards of Medical Care for Patients With Diabetes Mellitus
American Diabetes Association (2003) · Diabetes Care · doi:10.2337/diacare.26.2007.s33 · Cited by 609
HERMAN, G., STEVENS, C., VANDYCK, K., BERGMAN, A., YI, B., DESMET, M., SNYDER, K., HILLIARD, D., TANEN, M., & TANAKA, W. (2005) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2005.09.002 · Cited by 519
Herman, G. A., Bergman, A., Stevens, C., Kotey, P., Yi, B., Zhao, P., Dietrich, B., Golor, G., Schrodter, A., Keymeulen, B., et al. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-1009 · Cited by 495
Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes.
Holst, J. J., & Deacon, C. F. (1998) · Diabetes · doi:10.2337/diabetes.47.11.1663 · Cited by 487
Pospisilik, J. A., Martin, J., Doty, T., Ehses, J. A., Pamir, N., Lynn, F. C., Piteau, S., Demuth, H.-U., McIntosh, C. H. S., & Pederson, R. A. (2003) · Diabetes · doi:10.2337/diabetes.52.3.741 · Cited by 332
Cited by
Items 501–600 of 785
Fixed-dose combination of sitagliptin and metformin for the treatment of type 2 diabetes
Reynolds, J. (2009) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmsott.s4637 · Cited by 9
Managing Type 2 Diabetes in the Primary Care Setting: Beyond Glucocentricity
Kuritzky, L. (2010) · The American Journal of the Medical Sciences · doi:10.1097/maj.0b013e3181d64344 · Cited by 9
New drugs for the treatment of type 2 diabetes
Chowdhury, T. A., & Hossain, B. (2007) · British Journal of Hospital Medicine · doi:10.12968/hmed.2007.68.4.178 · Cited by 8
Park, S., Lee, H., Oh, J., Lim, K. S., Jang, I., Yu, K., Jung, J. H., & Kim, J.-A. (2015) · Drug Design Development and Therapy · doi:10.2147/dddt.s75980 · Cited by 8
McFarland, M. S., Cross, L. B., Gross, B., Gentry, C. K., Tunney, J., & Patel, U. P. (2009) · Journal of Managed Care Pharmacy · doi:10.18553/jmcp.2009.15.7.563 · Cited by 12
Incretin-based therapies for type 2 diabetes mellitus in Asian patients: Analysis of clinical trials
Louisa, M., Takeuchi, M., Takeuchi, M., Nafrialdi, N., & Setiabudy, R. (2010) · Medical Journal of Indonesia · doi:10.13181/mji.v19i3.406 · Cited by 10
Mamza, J., Mehta, R. L., Donnelly, R., & IDRIS, I. R. (2015) · Diabetes Therapy · doi:10.1007/s13300-015-0110-6 · Cited by 8
Campbell, I. W. (2007) · The British Journal of Diabetes · doi:10.1177/14746514070070051001 · Cited by 12
Therapeutic Options that Provide Glycemic Control and Weight Loss for Patients with Type 2 Diabetes
Blevins, T. (2010) · Postgraduate Medicine · doi:10.3810/pgm.2010.01.2111 · Cited by 8
Evidence-Based Practice Use of Incretin-Based Therapy in the Natural History of Diabetes
Schwartz, S. S. (2014) · Postgraduate Medicine · doi:10.3810/pgm.2014.05.2757 · Cited by 9
Nishimura, A., Usui, S., Kumashiro, N., Uchino, H., Yamato, A., Yasuda, D., Nagasawa, K., Okubo, M., Mori, Y., & Hirose, T. (2016) · Endocrine Journal · doi:10.1507/endocrj.ej16-0291 · Cited by 7
Role for DPP4 inhibitor therapy in cystic fibrosis related diabetes: A single centre experience
Santhakumar, A., Lewis, F., Pickles, J., Winterbottom, H., Punt, S., Beynon, J., Tofeec, K., Barry, P. J., & Brennan, A. L. (2024) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2024.06.007 · Cited by 7
Alanazi, A. (2014) · Saudi Pharmaceutical Journal · doi:10.1016/j.jsps.2013.12.018 · Cited by 9
Nishimura, T., Meguro, S., Sekioka, R., Tanaka, K., Saisho, Y., Irie, J., Tanaka, M., Kawai, T., & Itoh, H. (2015) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2015.02.031 · Cited by 8
Hasan, S. S., Aslam, Q., Islam, I., Kow, C. S., & Babar, Z. (2022) · Primary care diabetes · doi:10.1016/j.pcd.2022.01.008 · Cited by 7
Schnaars, Y., Gaikwad, S., Gottwald‐Hostalek, U., Uhl, W., Ribot, O., Varanasi, K. V., Rodríguez, L., Torrejón, J., & Gómez, L. (2022) · Diabetes Therapy · doi:10.1007/s13300-022-01349-2 · Cited by 12
Reghunath, S. R., Rashid, M., Chandran, V. P., Thunga, G., Shivashankar, K. N., & Acharya, L. D. (2023) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2023.102790 · Cited by 7
Pinelli, N. R., Nemerovski, C. W., & Koelling, T. M. (2011) · Transplantation Proceedings · doi:10.1016/j.transproceed.2011.02.059 · Cited by 7
Treating type 2 diabetes: incretin mimetics and enhancers
Janosz, K. E. N., Zalesin, K. C., Miller, W. M., & McCullough, P. A. (2009) · Therapeutic Advances in Cardiovascular Disease · doi:10.1177/1753944709341377 · Cited by 8
Wu, B., Hong, D., Xiao, Y., Zhao, Q., & Zheng, D. (2014) · Drug Design Development and Therapy · doi:10.2147/dddt.s70945 · Cited by 10
Cornell, S. A. (2014) · Journal of Diabetes & Metabolism · doi:10.4172/2155-6156.1000414 · Cited by 10
Kamalinia, S., Josse, R. G., Donio, P. J., Leduc, L., Shah, B. R., & Tobe, S. W. (2019) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.100 · Cited by 7
Metabolic Syndrome and Type 2 Diabetes: Can We Stop the Weight Gain with Diabetes?
Joffe, D. C., & Yanagisawa, R. T. (2007) · Medical Clinics of North America · doi:10.1016/j.mcna.2007.06.002 · Cited by 7
Åhrén, B. (2009) · Insulin · doi:10.1016/s1557-0843(09)80004-3 · Cited by 7
Sitagliptin — enhancing incretin action
Campbell, I. W., & Day, C. (2007) · The British Journal of Diabetes · doi:10.1177/14746514070070030601 · Cited by 7
Common crossroads in diabetes management
Valitutto, M. (2008) · Osteopathic Medicine and Primary Care · doi:10.1186/1750-4732-2-4 · Cited by 8
The role of incretin on diabetes mellitus.
Sanusi, H. D. (2009) · PubMed · Cited by 7
Special Features: Incretin-based therapies in type 2 diabetes mellitus
Cw, C., Jm, E., Chia, C. W., Egan, J. M., correspondence, A., & Egan, J. M. (2014) · Cited by 6
Improving glucagon-like peptide-1 dynamics in patients with type 2 diabetes mellitus.
Freeman, J. S. (2012) · PubMed · Cited by 6
Takahara, M., Shiraiwa, T., Katakami, N., Kaneto, H., Matsuoka, T., & Shimomura, I. (2014) · Endocrine Journal · doi:10.1507/endocrj.ej13-0466 · Cited by 6
Dipeptidyl Peptidase-4 Inhibitors in Diverse Patient Populations With Type 2 Diabetes
Hinnen, D. A. (2015) · The Science of Diabetes Self-Management and Care · doi:10.1177/0145721715609420 · Cited by 6
Yoshikawa, F., Uchino, H., Nagashima, T., Usui, S., Miyagi, M., Ando, Y., Kumashiro, N., & Hirose, T. (2021) · Diabetology International · doi:10.1007/s13340-021-00513-6 · Cited by 7
Lasalvia, P., Gil-Rojas, Y., & Peña, Á. A. G. (2022) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1080/14737167.2022.2044310 · Cited by 6
Postprandial physiology and the pathogenesis of type 2 diabetes mellitus
Davis, S. N. (2008) · Insulin · doi:10.1016/s1557-0843(08)80029-2 · Cited by 8
Halimi, S., Debaty, I., Villaret, L., & Müller, M. J. (2008) · La Revue de Médecine Interne · doi:10.1016/j.revmed.2008.05.011 · Cited by 15
Ampudia‐Blasco, F. J., & Ceriello, A. (2010) · Medicina Clínica · doi:10.1016/s0025-7753(10)70031-2 · Cited by 7
Candidate Dipeptidyl Peptidase-4 Inhibitors for the Treatment of Type 2 Diabetes
Jang, Y.-M., & Kim, D. (2011) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2011.35.2.117 · Cited by 6
Can Therapies That Target the Incretin System Improve Our Ability to Treat Type 2 Diabetes?
Bell, T. J., & Wright, E. E. (2010) · Journal of the National Medical Association · doi:10.1016/s0027-9684(15)30560-5 · Cited by 6
Khreit, O. I. G., Grant, H., & Henderson, C. (2016) · Journal of Drug Metabolism & Toxicology · doi:10.4172/2157-7609.1000220 · Cited by 6
for the JAMP Study Investigators, Ujihara, N., Sakura, H., Hashimoto, N., Sasamoto, K., Ohashi, H., Hasumi, S., Kasahara, T., Tomonaga, O., Nunome, H., et al. (2017) · Diabetology International · doi:10.1007/s13340-017-0330-2 · Cited by 6
Campbell, S. A., Light, P. E., & Simpson, S. H. (2019) · Diabetic Medicine · doi:10.1111/dme.14154 · Cited by 5
Ennis, G. E., Kohli, A., Jonaitis, E. M., Betthauser, T. J., Oh, J. M., Taylor, C. E., Chin, N. A., Koscik, R. L., Christian, B. T., Asthana, S., et al. (2021) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2021.04.028 · Cited by 6
Wu, L., Zhou, N., Sun, J.-Y., Yu, H., & Wang, R. (2021) · Journal of Cardiovascular Medicine · doi:10.2459/jcm.0000000000001270 · Cited by 6
New therapeutic options: management strategies to optimize glycemic control.
Freeman, J. S. (2010) · PubMed · Cited by 6
Katzeff, H. L., Williams‐Herman, D., Xu, L., Golm, G. T., Wang, H., Dong, Q., JOHNSON, J. R., O’Neill, E. A., Kaufman, K. D., Engel, S. S., et al. (2015) · Current Medical Research and Opinion · doi:10.1185/03007995.2015.1037259 · Cited by 8
Call for Comparative Effectiveness Research: Lowering A1c with Sitagliptin, Saxagliptin, or Cinnamon
Fairman, K. A., & Curtiss, F. R. (2009) · Journal of Managed Care Pharmacy · doi:10.18553/jmcp.2009.15.8.696 · Cited by 6
Multi‐target Drugs to Treat Metabolic Diseases
Lillich, F. F., Goorani, S., Proschak, E., & Imig, J. D. (2024) · Wiley eBooks · doi:10.1002/9781394182862.ch13 · Cited by 6
Que, L., Qin, W., Shi, Y., Ding, Y., Huang, K., Qian, Z., Huang, B., Zhou, P., & He, Q. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1105767 · Cited by 6
Clinical utility of fixed combinations of sitagliptin–metformin in treatment of type 2 diabetes
Green, J., Karen, K., & Cox, M. E. (2010) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmsott.s10195 · Cited by 13
Unintended positive and negative effects of drugs on lipoproteins
Siahmansur, T. J., Schofield, J. D., Azmi, S., Liu, Y., Durrington, P. N., & Soran, H. (2015) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000198 · Cited by 8
Kim, S. A., Shim, W. H., Lee, E. H., Lee, Y. M., Beom, S. H., Kim, E. S., Yoo, J. S., Nam, J. S., Cho, M. H., Park, J. S., et al. (2011) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2011.35.3.300 · Cited by 5
Targeting the Incretin System in Type 2 Diabetes Mellitus
Potenza, M. V., & Rayfield, E. J. (2009) · Mount Sinai Journal of Medicine A Journal of Translational and Personalized Medicine · doi:10.1002/msj.20112 · Cited by 6
Bhosle, D. S., Bhagat, A., Patil, A. D., Bobde, J., & Bhagat, A. A. (2015) · International Journal of Diabetes in Developing Countries · doi:10.1007/s13410-015-0370-8 · Cited by 5
Second steps in managing type 2 diabetes
Petersons, C. J. (2018) · Australian Prescriber · doi:10.18773/austprescr.2018.043 · Cited by 5
Mandal, P., Dan, S., Ghosh, B., Barma, S., Bose, R., & Pal, T. K. (2018) · INDIAN DRUGS · doi:10.53879/id.55.04.11242 · Cited by 5
Incretins: the novel therapy of type 2 diabetes.
Thongtang, N., & Sriwijitkamol, A. (2008) · PubMed · Cited by 6
Sitagliptin and metformin – novel combination therapy
Seyoum, B. (2011) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2011.556113 · Cited by 6
He, L., Liu, S., Shan, C., Tu, Y., Li, Z., & Zhang, X. D. (2016) · BMC Pharmacology and Toxicology · doi:10.1186/s40360-016-0084-7 · Cited by 8
Gliptins: DPP‐4 inhibitors to treat type 2 diabetes
Green, B., Flatt, P. R., & Bailey, C. J. (2007) · Future Prescriber · doi:10.1002/fps.33 · Cited by 9
Hayati, F., Al-Naemi, A. H., Sasongko, T. H., Hua, G. S., Mohamed, W. M. I. W., Daud, J., Yaacob, N. S., & Bebakar, W. M. W. (2014) · journal of Diabetes Research and Clinical Metabolism · doi:10.7243/2050-0866-3-10 · Cited by 5
Prise en charge du diabète de type 2 : anciens ou nouveaux médicaments, comment choisir ?
Halimi, S. (2013) · La Presse Médicale · doi:10.1016/j.lpm.2013.04.002 · Cited by 6
Current developments in the treatment of diabetes: the incretin therapies
Russell-Jones, D. L. (2010) · The British Journal of Diabetes · doi:10.1177/1474651409357266 · Cited by 6
Bain, S. C. (2009) · Endocrine Practice · doi:10.4158/ep08317.rar · Cited by 6
Shetty, A. S., Nandith, A., Snehalath, C., & Ramachandran, A. (2013) · PubMed · Cited by 5
Nauck, M. A., Schmidt, W. E., & Meier, J. J. (2007) · Springer eBooks · doi:10.1007/978-0-387-69737-6_12 · Cited by 5
Schubert, A., Buchholt, A. T., Khoury, A. C. E., Kamal, A., & Taieb, V. (2017) · Current Medical Research and Opinion · doi:10.1080/03007995.2017.1310091 · Cited by 5
Sitagliptin: A DPP-4 Inhibitor for the Treatment of Type 2 Diabetes Mellitus
Johnson, K., & Schurr, K. (2011) · Clinical Medicine Insights Therapeutics · doi:10.4137/cmt.s6227 · Cited by 5
A New Therapy of Type 2 Diabetes: DPP-4 Inhibitors
Ábel, T. (2011) · InTech eBooks · doi:10.5772/23604 · Cited by 4
Incretin physiology and its role in type 2 diabetes mellitus.
Svec, F. (2010) · PubMed · Cited by 6
Sitagliptin: an oral agent for glucose control
Bardsley, J. K., & Ratner, R. E. (2008) · Expert Review of Endocrinology & Metabolism · doi:10.1586/17446651.3.6.691 · Cited by 4
Clinical Management Strategies for Type 2 Diabetes
Cefalu, W. T., & Urquhart, S. (2007) · JAAPA · doi:10.1097/01720610-200712000-00002 · Cited by 4
Intensifying Treatment Beyond Monotherapy in Type 2 Diabetes Mellitus: Where Do Newer Therapies Fit?
Kuhn, A., Park, J., Ghazi, A., & Aroda, V. (2017) · Current Cardiology Reports · doi:10.1007/s11886-017-0832-3 · Cited by 4
Glycemic Control in Diabetic Patients on Long-Term Maintenance Dialysis
Aramwit, P., & Satirapoj, B. (2013) · InTech eBooks · doi:10.5772/52479 · Cited by 6
Sitagliptin as combination therapy in the treatment of type 2 diabetes mellitus
Miller, S. A. (2009) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmsott.s4068 · Cited by 13
New Approach to Chronic Cough: An Introductory Guide Based on Recent Clinical Practice Guidelines
Song, W., & Kim, S. (2019) · Korean Journal of Medicine · doi:10.3904/kjm.2019.94.6.471 · Cited by 5
Royer, C., Guay‐Bégin, A., Chanseau, C., Chevallier, P., Bordenave, L., Laroche, G., & Durrieu, M. (2020) · Journal of Biomedical Materials Research Part A · doi:10.1002/jbm.a.36918 · Cited by 5
Oral Agents for Type-2 Diabetes
Codario, R. A. (2010) · Humana Press eBooks · doi:10.1007/978-1-60327-441-8_6 · Cited by 4
New treatments for type 2 diabetes mellitus: combined therapy with sitagliptin
Gagliardino, J. J., Santoro, S., Arellano, S., & Girolamo, G. D. (2008) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.9.9.1495 · Cited by 4
Dipeptidyl peptidase-IV inhibitors: fixing type 2 diabetes?
McIntyre, H. F., & Grant, P. S. (2007) · British Journal of Hospital Medicine · doi:10.12968/hmed.2007.68.11.27682 · Cited by 4
Update in New Medications for Primary Care
Smetana, G. W., & Sillman, J. S. (2008) · Journal of General Internal Medicine · doi:10.1007/s11606-008-0823-6 · Cited by 4
Incretin enhancers, incretin mimetics – from therapeutic concept to clinical application
Winkler, G. (2007) · Orvosi Hetilap · doi:10.1556/oh.2007.28093 · Cited by 9
Novel Approaches to the Treatment of Type 2 Diabetes
Onge, E. S., Miller, S. A., & Taylor, J. R. (2009) · Journal of Pharmacy Practice · doi:10.1177/0897190008326578 · Cited by 6
Dapagliflozin combination therapy in type 2 diabetes mellitus
Yacoub, T. G. (2015) · Postgraduate Medicine · doi:10.1080/00325481.2016.1111119 · Cited by 6
Matuszek, B., Lenart-Lipińska, M., & Nowakowski, A. M. (2008) · PubMed · Cited by 7
Managing postprandial glucose levels in patients with diabetes.
Tenzer, P., & Brunton, S. (2008) · PubMed · Cited by 5
Neumiller, J. J., Odegard, P. S., White, J. R., Setter, S. M., & Campbell, R. K. (2008) · The Science of Diabetes Self-Management and Care · doi:10.1177/0145721708316620 · Cited by 4
Nauck, M. A., & Meier, J. J. (2015) · Wiley eBooks · doi:10.1002/9781118387658.ch48 · Cited by 4
Bhat, K. A., Singh, K. P., Maddukuri, H. R., Routray, S. N., Sharma, S., Sharma, S. K., Patel, K., Kinare, V., Mate, P., & Kumar, R. V. L. (2024) · Cureus · doi:10.7759/cureus.74820 · Cited by 3
SYSTEMATIC REVIEW ON MEDICAMENTS USED IN MANAGEMENT OF DIABETES MELLITUS
Jamwal, A. (2020) · International Journal of Pharmacy and Pharmaceutical Sciences · doi:10.22159/ijpps.2020v12i8.38345 · Cited by 5
Guo, L., Tian, F., Liu, L., Chen, M., Jiang, C., Li, S., Liu, C., Zhang, Y., Qin, J., Yu, D., et al. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15601 · Cited by 6
Raji, A., Long, J., Lam, R. L. H., O’Neill, E. A., & Engel, S. S. (2018) · Diabetes Therapy · doi:10.1007/s13300-018-0461-x · Cited by 3
Das, A. K., Gandhi, P., Saboo, B., Reddy, S. C., Chawla, R., Zargar, A. H., KOVIL, R. R., Chawla, M. S., Sharma, S., Gupta, S., et al. (2021) · Journal of Family Medicine and Primary Care · doi:10.4103/jfmpc.jfmpc_2378_20 · Cited by 7
Conroy, L., McCann, A., Zhang, N., & de Gaetano, M. (2024) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00695.2023 · Cited by 5
The Role of Incretins in Insulin Secretion
Schroeder, B. E., & Kolterman, O. (2009) · Springer eBooks · doi:10.1007/978-0-387-09841-8_4 · Cited by 3
Trunina, E. N., Petunina, N. A., & Chorbinskaya, S. A. (2011) · Diabetes Mellitus · doi:10.14341/2072-0351-5636 · Cited by 3
Barnett, A. H. (2007) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2007.01440.x · Cited by 3
Neue Konzepte in der Behandlung des Typ-2-Diabetes
Meier, J. J., Schmidt, W. E., & Klein, H.-H. (2007) · Der Internist · doi:10.1007/s00108-007-1876-z · Cited by 5
Treatment options for type 2 diabetes:introducing the incretin‐based therapies
Barnett, A. H. (2009) · Practical Diabetes · doi:10.1002/pdi.1367 · Cited by 3
Management of Unmet Needs in Type 2 Diabetes Mellitus: The Role of Incretin Agents
Goldenberg, R. (2011) · Canadian Journal of Diabetes · doi:10.1016/s1499-2671(11)80008-0 · Cited by 4
Pandit, R. S., Kelkar, A. S., & Bodhankar, S. L. (2013) · Biomedicine & Aging Pathology · doi:10.1016/j.biomag.2013.04.002 · Cited by 4
Metadata
- Authors
- Charbonnel, B., Karasik, A., Liu, J., Wu, M., Meininger, G., & for the Sitagliptin Study 020 Group
- Affiliations
- Centre Hospitalier Universitaire de Nantes (FR)
- Sheba Medical Center (IL)
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2006-12-01
- Volume
- 29
- Issue
- 12
- Pages
- 2638-2643
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2171512247
- Cited by
- 790
- References
- 12
- Citations by year
- 2026: 7 · 2025: 10 · 2024: 7 · 2023: 9 · 2022: 10 · 2021: 19 · 2020: 19 · 2019: 15 · 2018: 12 · 2017: 27 · 2016: 29 · 2015: 39 · 2014: 47 · 2013: 48 · 2012: 47
- FWCI
- 60.45
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- sitagliptin, DPP-4 inhibitors, metformin, type 2 diabetes, inadequate glycemic control, HbA1c, pioglitazone, insulin sensitivity, beta-cell function, hypoglycemia, gastrointestinal adverse effects, body weight
- MeSH terms
- Sitagliptin Phosphate, Adolescent, Adult, Aged, Blood Glucose, Diabetes Mellitus, Type 2, Drug Therapy, Combination, Female, Glycoproteins, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Insulin, Male, Metformin, Middle Aged, Placebos, Proinsulin, Protease Inhibitors, Pyrazines, Triazoles, Single-Blind Method, Dipeptidyl Peptidase 4, Dipeptidyl-Peptidase IV Inhibitors, Adenosine Deaminase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.